ArrayExpress Uploader0human32femaleIFN-K 240 microgram, 4 injectionsSLE168Caucasian32femaleIFN-K 240 microgram, 4 injectionsSLE112Caucasian32femaleIFN-K 240 microgram, 4 injectionsSLEnot specifiedCaucasian21femaleIFN-K 240 microgram, 4 injectionsSLE168Caucasian21femaleIFN-K 240 microgram, 4 injectionsSLE112Caucasian21femaleIFN-K 240 microgram, 4 injectionsSLEnot specifiedCaucasian46femaleIFN-K 240 microgram, 4 injectionsSLE168Caucasian46femaleIFN-K 240 microgram, 4 injectionsSLE112Caucasian46femaleIFN-K 240 microgram, 4 injectionsSLEnot specifiedCaucasian26femaleIFN-K 240 microgram, 3 injectionsSLE168Caucasian26femaleIFN-K 240 microgram, 3 injectionsSLE112Caucasian26femaleIFN-K 240 microgram, 3 injectionsSLEnot specifiedCaucasian45femaleIFN-K 240 microgram, 3 injectionsSLE168Caucasian45femaleIFN-K 240 microgram, 3 injectionsSLE112Caucasian45femaleIFN-K 240 microgram, 3 injectionsSLEnot specifiedCaucasian19femaleIFN-K 120 microgram, 4 injectionsSLE168Caucasian19femaleIFN-K 120 microgram, 4 injectionsSLE112Caucasian19femaleIFN-K 120 microgram, 4 injectionsSLEnot specifiedCaucasian50femaleIFN-K 120 microgram, 4 injectionsSLE168Caucasian50femaleIFN-K 120 microgram, 4 injectionsSLE112Caucasian50femaleIFN-K 120 microgram, 4 injectionsSLEnot specifiedCaucasian36femaleIFN-K 120 microgram, 4 injectionsSLE168Caucasian36femaleIFN-K 120 microgram, 4 injectionsSLE112Caucasian36femaleIFN-K 120 microgram, 4 injectionsSLEnot specifiedCaucasian25femaleIFN-K 120 microgram, 3 injectionsSLE168Caucasian25femaleIFN-K 120 microgram, 3 injectionsSLE112Caucasian25femaleIFN-K 120 microgram, 3 injectionsSLEnot specifiedCaucasian29femaleIFN-K 120 microgram, 3 injectionsSLE168Caucasian29femaleIFN-K 120 microgram, 3 injectionsSLE112Caucasian29femaleIFN-K 120 microgram, 3 injectionsSLEnot specifiedCaucasian46femaleIFN-K 120 microgram, 3 injectionsSLE168Caucasian46femaleIFN-K 120 microgram, 3 injectionsSLE112Caucasian46femaleIFN-K 120 microgram, 3 injectionsSLEnot specifiedCaucasian46femaleIFN-K 60 microgram, 4 injectionsSLE168Caucasian46femaleIFN-K 60 microgram, 4 injectionsSLE112Caucasian46femaleIFN-K 60 microgram, 4 injectionsSLEnot specifiedCaucasian42femaleIFN-K 60 microgram, 4 injectionsSLE168Caucasian42femaleIFN-K 60 microgram, 4 injectionsSLE112Caucasian42femaleIFN-K 60 microgram, 4 injectionsSLEnot specifiedCaucasian38femaleIFN-K 60 microgram, 4 injectionsSLE168Caucasian38femaleIFN-K 60 microgram, 4 injectionsSLE112Caucasian38femaleIFN-K 60 microgram, 4 injectionsSLEnot specifiedCaucasian37femaleIFN-K 60 microgram, 3 injectionsSLE168Caucasian37femaleIFN-K 60 microgram, 3 injectionsSLE112Caucasian37femaleIFN-K 60 microgram, 3 injectionsSLEnot specifiedCaucasian35femaleIFN-K 60 microgram, 3 injectionsSLE168Caucasian35femaleIFN-K 60 microgram, 3 injectionsSLE112Caucasian35femaleIFN-K 60 microgram, 3 injectionsSLEnot specifiedCaucasian33femaleIFN-K 30 micrograms, 3 injectionsSLE168Caucasian33femaleIFN-K 30 micrograms, 3 injectionsSLE112Caucasian33femaleIFN-K 30 micrograms, 3 injectionsSLEnot specifiedCaucasian28femaleIFN-K 30 micrograms, 3 injectionsSLE168Caucasian28femaleIFN-K 30 micrograms, 3 injectionsSLE112Caucasian28femaleIFN-K 30 micrograms, 3 injectionsSLEnot specifiedCaucasian47femaleIFN-K 30 micrograms, 3 injectionsSLE168Caucasian47femaleIFN-K 30 micrograms, 3 injectionsSLE112Caucasian47femaleIFN-K 30 micrograms, 3 injectionsSLEnot specifiedCaucasian50femaleplaceboSLE168Caucasian50femaleplaceboSLE112Caucasian50femaleplaceboSLEnot specifiedCaucasian44femaleplaceboSLE168Caucasian44femaleplaceboSLE112Caucasian44femaleplaceboSLEnot specifiedCaucasian39femaleplacebo and IV Solumedrol 1g between day 112 and day 168SLE168Caucasian39femaleplaceboSLE112Caucasian39femaleplaceboSLEnot specifiedCaucasian36femaleplaceboSLE168Caucasian36femaleplaceboSLE112Caucasian36femaleplaceboSLEnot specifiedCaucasian49femaleplaceboSLE168Asian49femaleplaceboSLE112Asian49femaleplaceboSLEnot specifiedAsian20femaleplaceboSLE168Caucasian20femaleplaceboSLE112Caucasian20femaleplaceboSLEnot specifiedCaucasian43femaleplaceboSLE168Caucasian43femaleplaceboSLE112Caucasian43femaleplaceboSLEnot specifiedCaucasian32femalein vitro IFNa-2b stimulation (4H)healthynot specifiedCaucasian32femalein vitro IFNa-Mix stimulation (4H)healthynot specifiedCaucasian23femalein vitro IFNa-2b stimulation (4H)healthynot specifiedCaucasian23femalein vitro IFNa-Mix stimulation (4H)healthynot specifiedCaucasian42femalein vitro IFNa-2b stimulation (4H)healthynot specifiedCaucasian42femalein vitro IFNa-Mix stimulation (4H)healthynot specifiedCaucasian46femalein vitro IFNa-2b stimulation (4H)healthynot specifiedCaucasian46femalein vitro IFNa-Mix stimulation (4H)healthynot specifiedCaucasian27femalein vitro IFNa-2b stimulation (4H)healthynot specifiedCaucasian27femalein vitro IFNa-Mix stimulation (4H)healthynot specifiedCaucasian24malein vitro IFNa-2b stimulation (4H)healthynot specifiedCaucasian24malein vitro IFNa-Mix stimulation (4H)healthynot specifiedCaucasian44malein vitro IFNa-2b stimulation (4H)healthynot specifiedCaucasian44malein vitro IFNa-Mix stimulation (4H)healthynot specifiedCaucasian24femalein vitro IFNa-2b stimulation (4H)healthynot specifiedNorth-African24femalein vitro IFNa-Mix stimulation (4H)healthynot specifiedNorth-African27femalein vitro IFNa-2b stimulation (4H)healthynot specifiedCaucasian27femalein vitro IFNa-Mix stimulation (4H)healthynot specifiedCaucasian20malenonehealthynot specifiedCaucasian43femalenonehealthynot specifiedCaucasian25femalenonehealthynot specifiedCaucasian32femalenonehealthynot specifiedCaucasian26malenonehealthynot specifiedCaucasian34malenonehealthynot specifiedCaucasian32femalenonehealthynot specifiedCaucasian42femalenonehealthynot specifiedCaucasian23femalenonehealthynot specifiedCaucasian27femalenonehealthynot specifiedCaucasian46femalenonehealthynot specifiedCaucasian24malenonehealthynot specifiedCaucasian36malenonehealthynot specifiedCaucasian24femalenonehealthynot specifiedCaucasian47femalenonehealthynot specifiedCaucasian41malenonehealthynot specifiedCaucasian31femalenonehealthynot specifiedCaucasian34femalenonehealthynot specifiedCaucasian27femalenonehealthynot specifiedCaucasian24femalenonehealthynot specifiedNorth-African44malenonehealthynot specifiedCaucasian43femalenonehealthynot specifiedCaucasian24femalenonehealthynot specifiedCaucasian37femalenonehealthynot specifiedCaucasian23femalenonehealthynot specifiedCaucasian43femalenonehealthynot specifiedCaucasian40malenonehealthynot specifiedCaucasian34malenonehealthynot specifiedCaucasian50femalenonehealthynot specifiedCaucasian24femalenonehealthynot specifiedCaucasian43femalenonehealthynot specifiedCaucasian42malenonehealthynot specifiedCaucasian19femalenonehealthynot specifiedCaucasian23malenonehealthynot specifiedCaucasian39femalenonehealthynot specifiedCaucasian41femalenonehealthynot specifiedCaucasian35femalenonehealthynot specifiedCaucasian37femalenonehealthynot specifiedCaucasian19femalenonehealthynot specifiedCaucasian34femalenonehealthynot specifiedCaucasian44femalenonehealthynot specifiedCaucasian35femalenonehealthynot specifiedCaucasian40femalenonehealthynot specifiedCaucasian38femalenonehealthynot specifiedCaucasian21femalenonehealthynot specifiedCaucasian41malenonehealthynot specifiedCaucasian2704arrayexpress_sid4We performed a phase I/II, randomized, double-blind, placebo-controlled dose-escalation study to examine the safety, immunogenicity, and...E-GEOD-39088/profile/8773/arrayexpressuploader6142lupus erythematosussystemic lupus erythematosusDec.12, 2014FalseE-GEOD-39088_A-AFFY-44down-regulation-of-interferon-signature-in-systemiDown-regulation of Interferon signature in systemic lupus erythematosus patients by active immunization with Interferon alpha-KinoidJul.12, 2014We performed a phase I/II, randomized, double-blind, placebo-controlled dose-escalation study to examine the safety, immunogenicity, and biological effects of active immunization with interferon alpha-Kinoid (IFN-K) in systemic lupus erythematosus (SLE) patients. Women 18-50 years of age with mild to moderate SLE were immunized with three (n=10) or four doses (n=9) of 30, 60, 120, 240 microgram IFN-K or saline. Anti-IFNalpha antibodies were detected in all IFN-K-immunized patients. Transcriptomic analysis separated patients at baseline into type I IFN signature-positive and -negative groups. IFN-K induced higher anti-IFNalpha titers in signature-positive than in signature-negative patients and, in signature-positive patients, reduced the expression of IFN-induced genes. The decrease in IFN score correlated with the anti-IFNalpha antibody titers, and with baseline IFN score. IFN-K or placebo was administered at day 0, day 7, day 28 in all patients. Half the subjects received a fourth injection at day 84 (see treatment protocol)http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39088http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39088/samples/